Search

Your search keyword '"Xu, Jian-Ming"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Xu, Jian-Ming" Remove constraint Author: "Xu, Jian-Ming" Database Unpaywall Remove constraint Database: Unpaywall
210 results on '"Xu, Jian-Ming"'

Search Results

5. Supplementary Table 5 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

6. Supplementary Table 2 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

7. Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

8. Supplementary Table 6 and Table 7 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

9. Supplementary Table 1 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

10. Supplementary Table 3 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

16. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer

17. Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)

19. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

21. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 trial (ORIENT-2)

22. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis

28. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial

29. Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

30. Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.

31. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

32. A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

39. Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.

40. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.

43. Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

45. Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

49. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

50. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Catalog

Books, media, physical & digital resources